Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS

K. L. Ferrante, J. Shefner, H. Zhang, R. Betensky, M. O'Brien, H. Yu, M. Fantasia, J. Taft, M. F. Beal, B. Traynor, K. Newhall, P. Donofrio, J. Caress, C. Ashburn, B. Freiberg, C. O'Neill, C. Paladenech, T. Walker, A. Pestronk, B. AbramsJ. Florence, R. Renna, J. Schierbecker, B. Malkus, M. Cudkowicz

Research output: Contribution to journalArticlepeer-review

Abstract

An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

Original languageEnglish (US)
Pages (from-to)1834-1836
Number of pages3
JournalNeurology
Volume65
Issue number11
DOIs
StatePublished - Dec 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS'. Together they form a unique fingerprint.

Cite this